Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

DxNA, llc. Announces New Equity Funding

Published: Monday, November 25, 2013
Last Updated: Monday, November 25, 2013
Bookmark and Share
DxNA, llc. announced the finalizing of an equity investment of $2.5 million by an individual investor.

The investment dollars will be used to complete the regulatory processes for the FDA 510(k) clearance of a Valley Fever (Coccidioidomycosis) assay on the GeneSTAT® system. The funding will also be used to initiate the regulatory processes for FDA 510(K) clearance and EEA CE-marking of a next-generation Staphylococcus Diagnostic Test the company calls its MRSA+ Assay.

The GeneSTAT® system is a rapid real-time PCR analyzer and cartridge system that is designed to be a simple to use, point of care system. The system has previously been validated for a CE-mark, which was obtained in 2011.

Valley Fever, called “A Silent Epidemic” by the CDC in a June 2013 article, is endemic to parts of California, Nevada, Utah, New Mexico, and Texas and the entire state of Arizona. As populations in those area increase and as more people travel through those areas, the exposure to and the risk of a significant number of infections is increasing each year. There are currently no FDA cleared PCR-based assays for diagnosing this disease that can be debilitating. Clearing this assay on a rapid, cost effective, point of care device will give the medical practitioner the option to quickly diagnose the symptomatic patient and prescribe appropriate monitoring and treatment before the disease reaches a debilitating stage.

The MRSA+ Assay, as previously mentioned, is a next generation Staphylococcus - assay that will detect and differentiate both Staphylococcus aureus and Coagulase Negative Staphylococcus in a sample and also detect which, if either, has the Methicillin resistant mec-A gene. On the GeneSTAT system this assay will, in about an hour, identify and differentiate infections caused by antibiotic resistant and/or non-resistant types of Staphylococcus thus providing information to the medical practitioner that is critical to treatment decisions that can save lives. This assay, upon regulatory clearance, is expected to be marketed in the United States as well as the EU.

“This funding is allowing us to press forward on the path we have been mapping out since we acquired the rights to both of these assays. This is an exciting time for DxNA, bringing us closer to entering the US and EU diagnostic markets with what we feel are ground breaking and distinguishing products.” says David Taus, CEO of DxNA, llc.

DxNA is a privately held company located in St. George Utah. It is a molecular diagnostics company that develops and distributes portable, fully-integrated systems and tests for infectious disease in the medical, agricultural, food safety, and biosecurity markets. The Company's systems and technologies enable rapid and precise molecular testing to take place on-site by allowing for otherwise complex laboratory procedures to be performed almost anywhere.

DxNA’s patented GeneSTAT® portable Real Time PCR molecular diagnostic testing system will allow individuals with minimal training to conduct accurate real-time diagnostic testing in virtually any location including laboratories, clinics, physician offices, emergency rooms or field settings. Designed with economy in mind, GeneSTAT is inherently less costly than the real time PCR systems typical of clinical laboratories.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DxNA to Acquire PathoGene
DxNA will acquire exclusive rights for Unit Dose Platform Applications of PathoGene’s multiplexed Staphylococcus MRSA+ assay on DxNA’s Real Time PCR GeneSTAT platform.
Monday, July 22, 2013
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
Detecting When Hormone Treatment for Breast Cancer Stops Working
Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment.
Packaging and Unpacking of the Genome
New research improves understanding of the importance of histone replacement.
New Way to Find DNA Damage
University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders.
How Different Treatments for Crohn's Effect the Microbiome
Different treatments for Crohn's disease in children affects their gut microbes in distinct ways, which has implications for future development of microbial-targeted therapies for these patients, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
Charting the 'Genomic Biography' of Leukemia
A new study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard offers a glimpse of the wealth of information that can be gleaned by combing the genome of a large collection of leukemia tissue samples.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos